Erasca, Inc. (ERAS)

Erasca's stock has experienced significant activity and growth, with a remarkable increase of 1,317.15% over the past year as of April 8, 2026. In March 2026, Erasca reported its Fourth Quarter and Full Year 2025 results, secured worldwide rights for ERAS-0015, and entered a clinical collaboration with Tango Therapeutics. In February 2026, the company announced a U.S. patent for ERAS-4001 and presented at conferences. In January 2026, Erasca completed an upsized public offering, raising approximately $258.8 million, and announced promising early clinical data for ERAS-0015. In December 2025, Erasca reported its Third Quarter 2025 results. In November 2025, a U.S. patent was issued for ERAS-0015.

As a clinical-stage precision oncology company, Erasca, Inc. does not yet generate significant revenue from product sales, so traditional demand seasonality is not applicable. The company's financial health and valuation are primarily driven by its cash runway, ability to raise capital, and the progress and results of its clinical trials and drug pipeline.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. The company utilizes a modality-agnostic approach, with product candidates including ERAS-0015, ERAS-4001, ERAS-12, and Naporafenib.

Erasca, Inc. is headquartered in San Diego, California, United States. The company has expanded its global reach by securing worldwide rights for ERAS-0015, including China, Hong Kong, and Macau.

Erasca's brand reputation over the past year appears to be largely positive, driven by significant clinical progress and successful financial activities. Promising early clinical data for ERAS-0015, successful financing rounds, strategic collaborations, and patent issuances have contributed to its positive reputation.

Erasca, Inc. has a diverse ownership structure, with institutional investors holding approximately 46.06% to 70.55% of the stock, insiders holding around 10.85% to 27.68%, and retail investors holding approximately 1.77% to 25.06%. Major institutional owners include Frazier Life Sciences Management, L.P., VR Adviser, LLC, and BlackRock, Inc. The largest individual shareholder is Jonathan E. Lim, who owns approximately 20.09% of the company's shares.